Voclosporin (Lupkynis)
Defines medical necessity criteria, initial and continued approval requirements, exclusions, dosing limits, prescriber and concomitant therapy requirements, and authorization durations for voclosporin (Lupkynis) across Commercial, ICHRA, and Medicaid lines of business.
Revised initial approval duration from 6 to 12 months and added Gazyva as an example of a biologic excluded for concurrent use; added ICHRA line of business.
Added exclusion for concurrent treatment with cyclophosphamide or a biologic and revised continued approval duration to 12 months.
Added criteria for member's treatment response and risk of worsening nephrotoxicity for requests exceeding >12 months and revised continued approval duration to 6 months (later changed back).
Template changes applied to other diagnoses/indications and continued therapy section.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.